of Berlin, who underwent unsuccessful stem-cell therapy for urinary incontinence, has won a court case against authorities of the University Hospital Innsbruck in Austria. He had claimed that the urologists who treated him had not told him the procedure was experimental.
Drug firms join forces to boost discovery pipeline

Pharmaceutical giants Merck, Pfizer and Eli
Lilly have joined forces in a start-up company that they hope will stimulate drug discovery.
Boston-based Enlight Biosciences will develop lab technologies to the 'pre-competitive' stage, so that each company will be able to use them to take its own research forward. The firm's leaders include a coalition of drug-development and academic 
'Fundamentally flawed' US pollution law thrown out
A US appeals court struck down landmark air-pollution regulations last week, shocking both environmental and industry groups with a decision that could severely hamper efforts to curb smog and acid rain. The decision came on the same day that the EPA said it would delay issuing the regulations on how to deal with carbon dioxide emissions that the Supreme Court had demanded. 
FDA aims for neutral tone in drug-rejection letters
In a move intended to stop investors from over-interpreting its decisions, the US Food and Drug Administration (FDA) will next month adopt a new system for delivering less-than-stellar news to companies trying to bring new drugs to market.
From 11 August, the agency will stop sending out its current genre of missives, which come in two categories: 'approvable' letters, if the drug needs more information or specific changes to win approval, and 'not approvable' letters, for applications with more major problems. In their place, a company whose drug is being rejected will receive a 'complete response' letter outlining an application's deficiencies and what can be done to address them.
Because the letters are private, investors will be able to infer little from a complete response except that a drug hasn't yet met the FDA's marketing standards. The change, says Janet Woodcock, the agency's top drugapproval official, will help the FDA to adopt "a more consistent and neutral way" of delivering the news that a drug application is not up to standard.
Efforts to curb pollution in the United States have suffered a legal set-back.
Lionfish not a roaring success for coral reefs
The red lionfish (Pterois volitans), a stunning Indo-Pacific species, is central to an invasive-species worst-case scenario that is playing out in the Atlantic Ocean. A study suggests that lionfish, with their voracious appetites, can reduce the survival of young fish on experimental reefs by 80%.
Eradicating the lionfish is now all but impossible in the Bahamas, warn the study's researchers. But conservationists in nearby regions in which lionfish have been spotted in smaller numbers, such as the Dominican Republic, could take steps to guard against the interlopers while there is still time.
The study was presented last week at an international corals conference in Fort Lauderdale, Florida. 
